


Balsalazide disodium dihydrate

Chemical Properties

CAS No. :	150399-21-6
Formula:	C17H17N3Na2O8
Molecular Weight:	437.31
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Balsalazide sodium hydrate (Balsalazide disodium) is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease. Balsalazide sodium hydrate is a new 5-aminosalicylic acid (5-ASA) containing prodrug. High dose Balsalazide sodium hydrate (3.0 g twice daily) was superior in maintaining remission in patients with ulcerative colitis compared with a low dose (1.5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated [1]. Balsalazide sodium hydrate is approved for the treatment of mild-to-moderate active UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile, with the added advantages of greater efficacy of remission induction and rapidity of onset [2].
Targets(IC50)	STAT, Interleukin

Solubility Information

Solubility	DMSO: 168.3 mg/mL (384.85 mM), Sonication is recommended. H2O: 198.9 mM, Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2867 mL	11.4335 mL	22.8671 mL
5 mM	0.4573 mL	2.2867 mL	4.5734 mL
10 mM	0.2287 mL	1.1434 mL	2.2867 mL
50 mM	0.0457 mL	0.2287 mL	0.4573 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. *Gut*, 2001. 49(6): p. 783-789.

Wiggins JB, et al. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. *Expert Opin Drug Metab Toxicol*, 2009. 5(10): p. 1279-1284.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481